Kiniksa Pharmaceuticals International, Plc

Health Care
Biotechnology: Pharmaceutical Preparations
www.kiniksa.com

Earnings Score
Moat Score

Market Cap $1.53B
PE -169
Debt $NaN
Cash $97.38M
EV $NaN
FCF $11.10M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$9.07M
EBIT	-$16.72M
ROE	-2%
ROA	-3%
FCF	$11.10M
Equity	$437.01M
Growth Stability	1
PE	-168.71
PEG	28.73
PB	3.5
P/FCF	137.78
P/S	3.98
Price/Cash	0.06
Net Margins	-11%
Op. Margins	-4%
Earnings CAGR	-1%
Sales Growth YoY	67%
Sales Growth QoQ	3%
Sales CAGR	2%
FCF CAGR	0%
Equity CAGR	7%
Earnings Stability	-0.32
Earnings Growth YoY	-8%

Earnings Growth QoQ	225%
Earnings CAGR 5Y	-6%
Sales CAGR 5Y	15%
FCF CAGR 5Y	2%
Equity CAGR 5Y	17%
Earnings CAGR 3Y	60%
Sales CAGR 3Y	60%
FCF CAGR 3Y	16%
Equity CAGR 3Y	44%
Market Cap	$1.53B
Revenue	$384.10M
Assets	$555.30M
Cash	$97.38M
Shares Outstanding	71.12M
Earnings Score	6%
Moat Score	8%
Working Capital	215.35M
Current Ratio	3.24
Shares Growth 3y	1%
Equity Growth QoQ	0%
Equity Growth YoY	8%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.

SEC Filings

Direct access to Kiniksa Pharmaceuticals International, Plc (KNSA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Kiniksa Pharmaceuticals International, Plc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Kiniksa Pharmaceuticals International, Plc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -1%

Stability -32%

loading chart...

Kiniksa Pharmaceuticals International, Plc Discounted Cash Flow

Fully customizable DCF calculator online for Kiniksa Pharmaceuticals International, Plc.

Years

Calculation mode

= $113M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$11M	$11M	$11M	$11M	$11M	$11M	$11M	$11M	$11M	$11M	$11M	$114M
DCF		$10M	$9.2M	$8.4M	$7.7M	$7M	$6.4M	$5.8M	$5.3M	$4.8M	$4.4M	$44M
Value	$113M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-	-410%	83%	5%	-11%
ROA	-	-32%	-64%	-45%	-67%	2%	-3%	-3%
ROE	-	-37%	-72%	-52%	-85%	46%	3%	-2%

Bad Net Margins (-11.41%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	471%	23%	15%
Earnings YoY growth	-	59%	57%	-0%	-2%	-216%	-92%	-6%
Equity YoY growth	-	-411%	-19%	38%	-41%	114%	11%	17%
FCF YoY growth	-	72%	87%	-15%	-7%	-104%	131%	2%